US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
CA2289702C
(en)
*
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
EP1080226A4
(de)
*
|
1998-05-21 |
2004-04-21 |
Isis Pharmaceuticals Inc |
Zusammensetzungen und methoden zur topischen verabreichung von oligonukleotiden
|
DK1077722T3
(da)
|
1998-05-22 |
2006-11-27 |
Ottawa Health Research Inst |
Fremgangsmåder og produkter til induktion af mukosaimmunitet
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US6852334B1
(en)
*
|
1999-04-20 |
2005-02-08 |
The University Of British Columbia |
Cationic peg-lipids and methods of use
|
US6576618B1
(en)
*
|
1999-06-22 |
2003-06-10 |
Research Development Foundation |
Methods to enhance wound healing and enhanced wound coverage material
|
AU769357B2
(en)
*
|
1999-07-15 |
2004-01-22 |
University Of British Columbia, The |
Methods for preparation of lipid-encapsulated therapeutic agents
|
US7094423B1
(en)
|
1999-07-15 |
2006-08-22 |
Inex Pharmaceuticals Corp. |
Methods for preparation of lipid-encapsulated therapeutic agents
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
AU780535B2
(en)
*
|
1999-08-27 |
2005-03-24 |
Inex Pharmaceuticals Corp. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
US7189705B2
(en)
*
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
WO2002028367A1
(fr)
|
2000-10-04 |
2002-04-11 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de revetement de particules fines avec un film de lipides
|
CA2426244A1
(en)
*
|
2000-10-25 |
2002-05-02 |
The University Of British Columbia |
Lipid formulations for target delivery
|
US20020146829A1
(en)
*
|
2000-11-29 |
2002-10-10 |
Aventis Pharmaceuticals Products Inc. |
Neutral and anionic colloidal particles for gene delivery
|
EP1345629A2
(de)
*
|
2000-12-29 |
2003-09-24 |
Advanced Inhalation Research, Inc. |
Inhalationspartikel mit verzögerter freigabe
|
DE10109897A1
(de)
*
|
2001-02-21 |
2002-11-07 |
Novosom Ag |
Fakultativ kationische Liposomen und Verwendung dieser
|
US20030077829A1
(en)
*
|
2001-04-30 |
2003-04-24 |
Protiva Biotherapeutics Inc.. |
Lipid-based formulations
|
EP1408932A4
(de)
|
2001-06-23 |
2009-02-25 |
Lyotropic Therapeutics Inc |
Teilchen mit verbesserter solubilisierungseigenschaft
|
US7125568B2
(en)
|
2001-08-23 |
2006-10-24 |
Sung Michael T |
Lipophilic drug compositions
|
EP1441763A2
(de)
*
|
2001-11-07 |
2004-08-04 |
Inex Pharmaceuticals Corp. |
Mukosale adjuvantien, die ein oligonukleotid und ein kationisch lipid enthält
|
GB0129121D0
(en)
*
|
2001-12-05 |
2002-01-23 |
Ic Vec Ltd |
Compound
|
AU2003213047A1
(en)
*
|
2002-02-13 |
2003-09-04 |
Medbridge, Inc. |
Protein carrier system for therapeutic oligonucleotides
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
EP3100719A3
(de)
|
2002-05-15 |
2017-02-22 |
California Pacific Medical Center |
Zuführung von nukleinsäureähnlichen verbindungen
|
DE60329497D1
(de)
|
2002-06-26 |
2009-11-12 |
Medigene Ag |
Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
|
JP4722481B2
(ja)
*
|
2002-06-28 |
2011-07-13 |
プロティバ バイオセラピューティクス リミテッド |
リポソーム製造方法および装置
|
US7785623B2
(en)
*
|
2002-10-01 |
2010-08-31 |
Keller Brian C |
Compositions and methods useful for the reduction of fine lines and wrinkles
|
US7231688B2
(en)
*
|
2002-10-18 |
2007-06-19 |
Panasonic Corporation Of North America |
Dirt cup for vacuum cleaner
|
JP2006512927A
(ja)
|
2002-12-11 |
2006-04-20 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
5’cpg核酸およびその使用方法
|
CN1753657A
(zh)
*
|
2003-02-11 |
2006-03-29 |
新药物公司 |
脂质体制剂的制备方法
|
EP1613285A2
(de)
*
|
2003-03-31 |
2006-01-11 |
Alza Corporation |
Fettpartikel mit asymmetrischer lipid-beschichtung und herstellungsverfahren dafür
|
EP1610763A2
(de)
*
|
2003-03-31 |
2006-01-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stabile liposome oder micellen mit einem sphingolipid und einem peg-lipopolymer
|
FR2853657B1
(fr)
*
|
2003-04-10 |
2005-06-24 |
Centre Nat Rech Scient |
Macromolecules auto assemblees et photopolymerisees autour de nanotubes de carbone, un procede pour leur preparation, et leurs applications
|
EP1617808A4
(de)
*
|
2003-04-25 |
2011-11-02 |
Penn State Res Found |
Verfahren und system für die systemische abgabe von wachstumshemmenden von lipiden stammenden bioaktiven verbindungen
|
EP1637144A4
(de)
*
|
2003-05-30 |
2010-01-13 |
Nippon Shinyaku Co Ltd |
Oligonucleinsäure enthaltender komposit und diesen enthaltende pharmazeutische zusammensetzung
|
EP2567693B1
(de)
*
|
2003-07-16 |
2015-10-21 |
Protiva Biotherapeutics Inc. |
Interferierende, in Lipiden eingekapselte RNA
|
CA2536333C
(en)
*
|
2003-08-28 |
2013-01-08 |
Jan Weiler |
Interfering rna duplex having blunt-ends and 3'-modifications
|
AU2004272646B2
(en)
*
|
2003-09-15 |
2011-11-24 |
Arbutus Biopharma Corporation |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
JP2007509040A
(ja)
*
|
2003-10-11 |
2007-04-12 |
イネックス ファーマシューティカルズ コーポレイション |
先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
EP1731173A1
(de)
*
|
2004-03-10 |
2006-12-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Komplexe teilchen und beschichtete komplexe teilchen
|
EP2471923B1
(de)
|
2004-05-28 |
2014-08-20 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen mit microRNA
|
US7807647B2
(en)
*
|
2004-06-01 |
2010-10-05 |
Pronai Therapeutics, Inc. |
Methods and compositions for cancer therapy
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20050287667A1
(en)
*
|
2004-06-01 |
2005-12-29 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
JP2008504827A
(ja)
|
2004-07-02 |
2008-02-21 |
プロチバ バイオセラピューティクス インコーポレイティッド |
免疫賦活性siRNA分子およびその使用方法
|
US20060116270A1
(en)
*
|
2004-07-16 |
2006-06-01 |
Mehdi Hatamian |
Centrifuge system
|
JP2006036448A
(ja)
*
|
2004-07-27 |
2006-02-09 |
Sony Corp |
排紙トレー、給排紙装置、画像形成装置、及び情報表示装置
|
WO2006044996A2
(en)
*
|
2004-10-15 |
2006-04-27 |
The Trustees Of Columbia University In The City Of New York |
System and method for automated boundary detection of body structures
|
US11660317B2
(en)
|
2004-11-08 |
2023-05-30 |
The Johns Hopkins University |
Compositions comprising cardiosphere-derived cells for use in cell therapy
|
EP2302051B1
(de)
|
2004-11-12 |
2015-01-07 |
Asuragen, Inc. |
Verfahren und Zusammensetzungen, die miRNAs und miRNA-inhibitorischen Molekülen verbunden sind
|
AU2005303389A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
US20060134189A1
(en)
*
|
2004-11-17 |
2006-06-22 |
Protiva Biotherapeutics, Inc |
siRNA silencing of apolipoprotein B
|
EP1811960A2
(de)
*
|
2004-11-19 |
2007-08-01 |
Novosom AG |
Verbesserungen von oder im zusammenhang mit pharmazeutischen zusammensetzungen zur lokalen verabreichung
|
US10687785B2
(en)
|
2005-05-12 |
2020-06-23 |
The Trustees Of Columbia Univeristy In The City Of New York |
System and method for electromechanical activation of arrhythmias
|
JP5368793B2
(ja)
|
2005-07-18 |
2013-12-18 |
ユニバーシティ オブ マサチューセッツ ロウエル |
ナノエマルジョンを製造および使用するための組成物および方法
|
JP5639338B2
(ja)
*
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US20120021042A1
(en)
*
|
2005-09-15 |
2012-01-26 |
Steffen Panzner |
Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
|
EP1764091B1
(de)
*
|
2005-09-15 |
2017-08-30 |
Marina Biotech, Inc. |
Verbesserungen für, oder in Bezug auf amphotere Liposomen
|
US20070087045A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Industrial Technology Research Institute |
Lipid carrier and method of preparing the same
|
JP5336853B2
(ja)
|
2005-11-02 |
2013-11-06 |
プロチバ バイオセラピューティクス インコーポレイティッド |
修飾siRNA分子およびその使用法
|
WO2007064945A2
(en)
|
2005-12-01 |
2007-06-07 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
US9486408B2
(en)
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
US8367628B2
(en)
|
2005-12-01 |
2013-02-05 |
Pronai Therapeutics, Inc. |
Amphoteric liposome formulation
|
WO2007080902A1
(ja)
|
2006-01-11 |
2007-07-19 |
Kyowa Hakko Kogyo Co., Ltd. |
眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
|
EP2004141A2
(de)
*
|
2006-03-17 |
2008-12-24 |
Novosom AG |
Effizientes verfahren zum beladen von amphoteren liposomen mit nukleinsäure-wirkstoffen
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
WO2008022468A1
(en)
*
|
2006-08-24 |
2008-02-28 |
British Columbia Cancer Agency Branch |
Compositions and methods for treating myelosuppression
|
CA2663962A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
JP2010504350A
(ja)
*
|
2006-09-19 |
2010-02-12 |
アシュラジェン インコーポレイテッド |
治療的介入の標的としての、miR−200によって調節される遺伝子および経路
|
EP2695608B1
(de)
*
|
2006-10-03 |
2016-11-23 |
Arbutus Biopharma Corporation |
Lipidhaltige Formulierungen
|
AU2007306556B2
(en)
|
2006-10-13 |
2014-04-10 |
Marina Biotech, Inc. |
Improvements in or relating to amphoteric liposomes
|
MX2009005727A
(es)
|
2006-12-01 |
2009-08-27 |
Anterios Inc |
Nanoparticulas de entidad anfifilica.
|
KR20150028308A
(ko)
|
2006-12-01 |
2015-03-13 |
안테리오스, 인코퍼레이티드 |
펩티드 나노입자 및 이의 용도
|
EP2104735A2
(de)
*
|
2006-12-08 |
2009-09-30 |
Asuragen, INC. |
Mir-21-regulierte gene und pfade als ziele für therapeutische interventionen
|
AU2007333109A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Functions and targets of let-7 micro RNAs
|
CN101622348A
(zh)
*
|
2006-12-08 |
2010-01-06 |
奥斯瑞根公司 |
作为治疗性干预靶标的miR-20调节的基因和途径
|
US8785409B2
(en)
|
2007-01-30 |
2014-07-22 |
Geron Corporation |
Compounds having anti-adhesive effects on cancer cells
|
JP5415283B2
(ja)
*
|
2007-02-07 |
2014-02-12 |
グラダリス インク. |
シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
|
EP3434259A1
(de)
|
2007-05-04 |
2019-01-30 |
Marina Biotech, Inc. |
Aminosäurelipide und verwendungen davon
|
US20090131354A1
(en)
*
|
2007-05-22 |
2009-05-21 |
Bader Andreas G |
miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
US20090232893A1
(en)
*
|
2007-05-22 |
2009-09-17 |
Bader Andreas G |
miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
|
KR20100050443A
(ko)
*
|
2007-05-31 |
2010-05-13 |
안테리오스, 인코퍼레이티드 |
핵산 나노입자 및 이의 용도
|
WO2008154333A2
(en)
*
|
2007-06-08 |
2008-12-18 |
Asuragen, Inc. |
Mir-34 regulated genes and pathways as targets for therapeutic intervention
|
US8716255B2
(en)
|
2007-08-10 |
2014-05-06 |
British Columbia Cancer Agency Branch |
Microrna compositions and methods for the treatment of myelogenous leukemia
|
EP2198050A1
(de)
|
2007-09-14 |
2010-06-23 |
Asuragen, INC. |
Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon
|
JP5711535B2
(ja)
*
|
2007-10-12 |
2015-05-07 |
マリーナ バイオテック,インコーポレイテッド |
中性脂質を含む両性リポソーム
|
AU2014240370B2
(en)
*
|
2007-10-12 |
2016-08-25 |
Biontech Delivery Technologies Gmbh |
Amphoteric liposomes comprising neutral lipids
|
US8071562B2
(en)
*
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US8106022B2
(en)
|
2007-12-04 |
2012-01-31 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
WO2009086156A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Asuragen, Inc. |
Mir-10 regulated genes and pathways as targets for therapeutic intervention
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
EP2224912B1
(de)
*
|
2008-01-02 |
2016-05-11 |
TEKMIRA Pharmaceuticals Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
US20090263803A1
(en)
*
|
2008-02-08 |
2009-10-22 |
Sylvie Beaudenon |
Mirnas differentially expressed in lymph nodes from cancer patients
|
EP3643782A1
(de)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modifizierte rnai-polynukleotide und verwendungen davon
|
EP2268832A2
(de)
*
|
2008-03-06 |
2011-01-05 |
Asuragen, INC. |
Microrna-marker für das wiederauftreten eines kolorektalkarzinoms
|
EP2271757A2
(de)
*
|
2008-03-26 |
2011-01-12 |
Asuragen, INC. |
Zusammensetzungen und verfahren in zusammenhang mit mir-16 und prostatakrebstherapie
|
US20090258928A1
(en)
*
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
JP5475753B2
(ja)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
核酸送達用の脂質製剤
|
EP2281041B1
(de)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Abdämpfen der csn5 genexpression unter verwendung von interferierender rns
|
US8258111B2
(en)
*
|
2008-05-08 |
2012-09-04 |
The Johns Hopkins University |
Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
|
WO2009149418A2
(en)
*
|
2008-06-06 |
2009-12-10 |
Asuragen, Inc. |
Novel compositions for the in vivo delivery of rnai agents
|
RU2510280C2
(ru)
|
2008-06-27 |
2014-03-27 |
Пфайзер Инк. |
Новые адъювантные композиции
|
BRPI0915774B1
(pt)
*
|
2008-07-15 |
2019-11-05 |
3 Nine Ab |
método para capturar patógenos aerotransportados carregados positiva ou negativamente
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
TW201004658A
(en)
*
|
2008-07-31 |
2010-02-01 |
Enzon Pharmaceuticals Inc |
Nanoparticle compositions for nucleic acids delivery system
|
WO2010014977A1
(en)
|
2008-08-01 |
2010-02-04 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for matching and imaging tissue characteristics
|
CN105030809A
(zh)
|
2008-08-01 |
2015-11-11 |
协和发酵麒麟株式会社 |
抑制靶基因表达的组合物
|
WO2010030819A1
(en)
|
2008-09-10 |
2010-03-18 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for opening a tissue
|
WO2010033246A1
(en)
|
2008-09-22 |
2010-03-25 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
US9139554B2
(en)
*
|
2008-10-09 |
2015-09-22 |
Tekmira Pharmaceuticals Corporation |
Amino lipids and methods for the delivery of nucleic acids
|
CA2741373A1
(en)
|
2008-10-30 |
2010-06-03 |
Peixuan Guo |
Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
|
NO2355851T3
(de)
|
2008-11-10 |
2018-09-01 |
|
|
US20100179213A1
(en)
*
|
2008-11-11 |
2010-07-15 |
Mirna Therapeutics, Inc. |
Methods and Compositions Involving miRNAs In Cancer Stem Cells
|
WO2010057155A1
(en)
*
|
2008-11-17 |
2010-05-20 |
Enzon Pharmaceuticals, Inc. |
Releasable cationic lipids for nucleic acids delivery systems
|
WO2010057160A1
(en)
*
|
2008-11-17 |
2010-05-20 |
Enzon Pharmaceuticals, Inc. |
Releasable fusogenic lipids for nucleic acids delivery systems
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
AU2010208035B2
(en)
|
2009-01-29 |
2016-06-23 |
Arbutus Biopharma Corporation |
Improved lipid formulation for the delivery of nucleic acids
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
AU2010223967B2
(en)
|
2009-03-12 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2010107957A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010107958A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
SG174452A1
(en)
|
2009-03-19 |
2011-10-28 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
|
WO2010111471A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2411520A2
(de)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
Rna-interferenz-vermittelte hemmung der genexpression von tslp (thymic stromal lymphopoietin) unter verwendung von sina (short interfering nucleic acid)
|
MX2011010072A
(es)
|
2009-03-27 |
2011-10-06 |
Merck Sharp & Dohme |
Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
|
US20100285112A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Tatiana Novobrantseva |
Methods of delivering oligonucleotides to immune cells
|
SG10201911942UA
(en)
|
2009-05-05 |
2020-02-27 |
Muthiah Manoharan |
Lipid compositions
|
CN102625696B
(zh)
|
2009-06-10 |
2015-06-03 |
阿尔尼拉姆医药品有限公司 |
改进的脂质制剂
|
IL292615B2
(en)
|
2009-07-01 |
2023-11-01 |
Protiva Biotherapeutics Inc |
Nucleic acid-lipid particles, preparations containing them and their uses
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
EP2823810B9
(de)
|
2009-07-09 |
2019-10-30 |
Novosom Verwaltungs GmbH |
Nachahmung von Lipoproteinstrukturen
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
EP2810643A3
(de)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus
|
US10058837B2
(en)
|
2009-08-28 |
2018-08-28 |
The Trustees Of Columbia University In The City Of New York |
Systems, methods, and devices for production of gas-filled microbubbles
|
EP2480144B1
(de)
|
2009-09-21 |
2024-03-06 |
The Trustees of Columbia University in the City of New York |
Systeme zur öffnung einer gewebebarriere
|
US9222086B2
(en)
|
2009-09-23 |
2015-12-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
WO2011056682A1
(en)
|
2009-10-27 |
2011-05-12 |
The University Of British Columbia |
Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
|
RU2573409C2
(ru)
|
2009-11-04 |
2016-01-20 |
Дзе Юниверсити Оф Бритиш Коламбиа |
Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
|
PT2506857T
(pt)
|
2009-12-01 |
2018-05-14 |
Translate Bio Inc |
Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
|
US9687550B2
(en)
|
2009-12-07 |
2017-06-27 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
EP2512449B1
(de)
*
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
|
WO2011119058A2
(en)
|
2010-03-22 |
2011-09-29 |
Universidade De Coimbra |
F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
|
IL265674B2
(en)
|
2010-03-24 |
2024-05-01 |
Phio Pharm Corp |
Rana disorder in cutaneous and fibrotic symptoms
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
EP2550001B1
(de)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna-interferenz bei augenerkrankungen
|
EP3391877A1
(de)
|
2010-04-08 |
2018-10-24 |
The Trustees of Princeton University |
Herstellung von lipidnanopartikeln
|
EP2382994A1
(de)
|
2010-04-26 |
2011-11-02 |
Maurizio Victor Cattaneo |
Durch Liganden gezielrichtete Nanokapseln zur Verabreichung von RNAi und anderen Wirkstoffen
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
WO2011136369A1
(ja)
|
2010-04-28 |
2011-11-03 |
協和発酵キリン株式会社 |
カチオン性脂質
|
US20130101521A1
(en)
*
|
2010-05-01 |
2013-04-25 |
The Trustees Of Columbia University In The City Of New York |
Methods devices and systems of preparing targeted microbubble shells
|
JP2013527856A
(ja)
|
2010-05-12 |
2013-07-04 |
プロチバ バイオセラピューティクス インコーポレイティッド |
陽イオン性脂質およびその使用方法
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
KR101198715B1
(ko)
|
2010-05-14 |
2012-11-13 |
한국생명공학연구원 |
핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
|
CA2800401C
(en)
|
2010-06-03 |
2020-09-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
CA2802994A1
(en)
|
2010-06-17 |
2011-12-22 |
The United States Of America As Represented By The Secretary, National I Nstitutes Of Health |
Compositions and methods for treating inflammatory conditions
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
DK3243526T3
(da)
|
2010-07-06 |
2020-02-17 |
Glaxosmithkline Biologicals Sa |
Levering af rna til at udløse flere immunsignalveje
|
EP2590626B1
(de)
|
2010-07-06 |
2015-10-28 |
GlaxoSmithKline Biologicals SA |
Liposomen aus lipiden, die einen vorteilhaften pka-wert zur verabreichung von rna besitzen
|
CN106421773A
(zh)
|
2010-07-06 |
2017-02-22 |
诺华股份有限公司 |
自我复制rna分子的病毒样递送颗粒
|
CA3169291A1
(en)
|
2010-07-06 |
2012-01-12 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of rna
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
EP4079856A1
(de)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
|
EP2609198B8
(de)
|
2010-08-24 |
2018-03-28 |
Sirna Therapeutics, Inc. |
Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
|
EP2609106A4
(de)
|
2010-08-26 |
2014-03-19 |
Merck Sharp & Dohme |
Durch rna-interferenz vermittelte inhibition der prolyl-hydroxylase-domäne-2 (phd2)-genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
HRP20221533T1
(hr)
|
2010-08-31 |
2023-02-17 |
Glaxosmithkline Biologicals Sa |
Pegilirani liposomi za isporuku rna koja kodira imunogen
|
SI4008357T1
(sl)
|
2010-08-31 |
2023-04-28 |
Glaxosmithkline Biologicals Sa |
Mali liposomi za dostavo imunogen-kodirajoče RNA
|
MX363307B
(es)
|
2010-10-11 |
2019-03-20 |
Novartis Ag Star |
Plataformas para suministro de antigenos.
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
AU2012207606B2
(en)
|
2011-01-11 |
2017-02-23 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
US20140039034A1
(en)
|
2011-01-19 |
2014-02-06 |
Fumikazu SHINOHARA |
Composition for suppressing expression of target gene
|
US10849975B2
(en)
|
2011-02-03 |
2020-12-01 |
Thomas Jefferson University |
Multivalent vaccines for rabies virus and filoviruses
|
WO2012162664A1
(en)
|
2011-05-26 |
2012-11-29 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for opening of a tissue barrier in primates
|
AU2012267578B2
(en)
|
2011-06-08 |
2017-04-20 |
Translate Bio, Inc. |
Cleavable lipids
|
US10196637B2
(en)
|
2011-06-08 |
2019-02-05 |
Nitto Denko Corporation |
Retinoid-lipid drug carrier
|
US9011903B2
(en)
|
2011-06-08 |
2015-04-21 |
Nitto Denko Corporation |
Cationic lipids for therapeutic agent delivery formulations
|
CA3107288A1
(en)
|
2011-06-08 |
2012-12-13 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
JP2014520806A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
Rna分子の送達のための有用なn:p比を有するリポソーム
|
EP2729165B1
(de)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogene kombinationszusammensetzungen und ihre verwendung
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
WO2013040251A2
(en)
|
2011-09-13 |
2013-03-21 |
Asurgen, Inc. |
Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
|
CA2849476A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
JP2013095755A
(ja)
|
2011-11-02 |
2013-05-20 |
Kyowa Hakko Kirin Co Ltd |
カチオン性脂質
|
RU2647476C2
(ru)
|
2011-11-04 |
2018-03-15 |
Нитто Денко Корпорейшн |
Способ получения липидных наночастиц для доставки лекарственного средства
|
US9579338B2
(en)
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
WO2013075132A1
(en)
|
2011-11-17 |
2013-05-23 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Therapeutic rna switches compositions and methods of use
|
DE21212055T1
(de)
|
2011-12-07 |
2022-08-04 |
Alnylam Pharmaceuticals, Inc. |
Biologisch abbaubare lipide zur freisetzung von wirkstoffen
|
TWI594767B
(zh)
|
2011-12-12 |
2017-08-11 |
協和醱酵麒麟有限公司 |
含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
|
AU2012353463B2
(en)
|
2011-12-12 |
2017-08-24 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nanoparticles containing combinations of cationic lipids
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
BR112014021068A8
(pt)
|
2012-02-21 |
2018-01-23 |
Centre National De La Recherce Scient |
inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
|
US20160015808A1
(en)
|
2012-02-21 |
2016-01-21 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Tam receptors as virus entry cofactors
|
KR20220045089A
(ko)
|
2012-02-24 |
2022-04-12 |
아뷰터스 바이오파마 코포레이션 |
트리알킬 양이온성 지질 및 그의 사용 방법
|
CA2868030C
(en)
|
2012-03-29 |
2021-05-25 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
TW201726600A
(zh)
|
2012-07-06 |
2017-08-01 |
協和醱酵麒麟有限公司 |
陽離子性脂質
|
CA2878314A1
(en)
*
|
2012-07-16 |
2014-01-23 |
Kyowa Hakko Kirin Co., Ltd. |
Rnai pharmaceutical composition for suppressing expression of kras gene
|
CA2875391A1
(en)
|
2012-07-27 |
2014-01-30 |
Institut National De La Sante Et De La Recherche Medicale |
Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
|
JP6433896B2
(ja)
|
2012-08-13 |
2018-12-05 |
シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center |
組織再生のためのエキソソームおよびマイクロリボ核酸
|
CN104884065B
(zh)
|
2012-09-21 |
2019-01-01 |
强烈治疗剂公司 |
治疗癌症的方法
|
WO2014059170A1
(en)
|
2012-10-10 |
2014-04-17 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for mechanical mapping of cardiac rhythm
|
KR20150087270A
(ko)
|
2012-11-05 |
2015-07-29 |
프로나이 테라퓨틱스, 인코포레이티드 |
Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
|
EP2970955B1
(de)
|
2013-03-14 |
2018-11-14 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
EA037922B1
(ru)
|
2013-03-14 |
2021-06-07 |
Шир Хьюман Дженетик Терапис, Инк. |
мРНК CFTR И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ МУКОВИСЦИДОЗА У МЛЕКОПИТАЮЩЕГО
|
PE20211393A1
(es)
|
2013-03-14 |
2021-07-27 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
|
EP2971013B1
(de)
|
2013-03-15 |
2020-08-19 |
The University Of British Columbia |
Lipidnanopartikel zur transfektion und zugehörige verfahren
|
AR096203A1
(es)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos
|
US9247921B2
(en)
|
2013-06-07 |
2016-02-02 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods of high frame rate streaming for treatment monitoring
|
EP3033325B1
(de)
|
2013-07-23 |
2019-12-04 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur abgabe von boten-rna
|
AU2014292926B2
(en)
|
2013-07-25 |
2020-03-05 |
Exicure Operating Company |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
US10322178B2
(en)
|
2013-08-09 |
2019-06-18 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for targeted drug delivery
|
US10028723B2
(en)
|
2013-09-03 |
2018-07-24 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods for real-time, transcranial monitoring of blood-brain barrier opening
|
EP3049105B1
(de)
|
2013-09-19 |
2020-12-30 |
Moredun Research Institute |
Impfstoff
|
EP4276176A3
(de)
|
2013-10-22 |
2024-01-10 |
Translate Bio, Inc. |
Mrna-therapie für argininosuccinat-synthase-mangel
|
EA034103B1
(ru)
|
2013-10-22 |
2019-12-27 |
Транслейт Био, Инк. |
СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
JP6772062B2
(ja)
|
2013-12-02 |
2020-10-21 |
フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. |
癌の免疫療法
|
AU2015217301A1
(en)
|
2014-02-11 |
2016-08-25 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
JP6571679B2
(ja)
|
2014-04-25 |
2019-09-04 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの精製方法
|
EP3137119B1
(de)
|
2014-04-28 |
2020-07-01 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
|
EP3146049B1
(de)
|
2014-05-22 |
2020-02-26 |
Alnylam Pharmaceuticals, Inc. |
Angiotensinogen (agt)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2016023148A
(ja)
*
|
2014-07-17 |
2016-02-08 |
富士フイルム株式会社 |
脂質粒子の製造法および脂質粒子を有する核酸送達キャリア
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
CN107208095B
(zh)
|
2014-10-02 |
2021-11-16 |
阿布特斯生物制药公司 |
用于使乙型肝炎病毒基因表达沉默的组合物和方法
|
WO2016054591A1
(en)
|
2014-10-03 |
2016-04-07 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
MX2017009306A
(es)
|
2015-01-16 |
2017-11-08 |
Zoetis Services Llc |
Vacuna contra la fiebre aftosa.
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
CA2980721C
(en)
|
2015-03-24 |
2023-10-24 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
MX2017012610A
(es)
|
2015-04-08 |
2018-03-16 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
US20180245074A1
(en)
|
2015-06-04 |
2018-08-30 |
Protiva Biotherapeutics, Inc. |
Treating hepatitis b virus infection using crispr
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
WO2017007813A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
EP3329003A2
(de)
|
2015-07-29 |
2018-06-06 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur ausschaltung einer hepatitis-b-virus-genexpression
|
US9856481B2
(en)
|
2015-08-13 |
2018-01-02 |
Ann & Robert H. Lurie Children's Hospital |
MicroRNA treatment of fibrosis
|
AU2016312530A1
(en)
|
2015-08-24 |
2018-03-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
KR20180051550A
(ko)
|
2015-09-02 |
2018-05-16 |
알닐람 파마슈티칼스 인코포레이티드 |
프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
|
EP3350328A1
(de)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Gegen patatin-like-phospholipasedomäne gerichtete polynukleotidmittel mit 3 (pnpla3) und verfahren zur verwendung davon
|
WO2017070151A1
(en)
|
2015-10-19 |
2017-04-27 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
|
EP3395797A4
(de)
|
2015-12-25 |
2019-09-04 |
Kyowa Hakko Kirin Co., Ltd. |
Verbindungen als kationische lipide
|
US11253551B2
(en)
|
2016-01-11 |
2022-02-22 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
|
US20170360815A1
(en)
|
2016-02-25 |
2017-12-21 |
Applied Biological Laboratories, Inc. |
Compositions and methods for protecting against airborne pathogens and irritants
|
KR20180120204A
(ko)
|
2016-02-25 |
2018-11-05 |
어플라이드 바이올로지컬 래버러토리즈 인코포레이티드 |
공기 매개 병원체 및 자극물질에 대한 보호용 조성물 및 방법
|
EP3439695B1
(de)
|
2016-04-04 |
2022-05-04 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Multivalente impfstoffe gegen tollwut- und coronaviren
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
JP7080826B2
(ja)
*
|
2016-05-16 |
2022-06-06 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
|
US11351200B2
(en)
|
2016-06-03 |
2022-06-07 |
Cedars-Sinai Medical Center |
CDC-derived exosomes for treatment of ventricular tachyarrythmias
|
KR102519244B1
(ko)
|
2016-06-07 |
2023-04-06 |
더 제이. 데이비드 글래드스톤 인스티튜트, 어 테스터멘터리 트러스트 이스타빌리쉬드 언더 더 윌 오브제이. 데이비드 글래드스톤 |
베타-히드록시부티레이트 및 부탄디올의 중쇄 지방산 에스테르 및 이것을 사용하는 조성물 및 이것을 사용하는 방법
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
EP3478838A1
(de)
|
2016-06-30 |
2019-05-08 |
Arbutus Biopharma Corporation |
Zusammensetzungen und verfahren zur abgabe von boten-rna
|
MX2019002339A
(es)
|
2016-09-02 |
2019-05-16 |
Dicerna Pharmaceuticals Inc |
Analogos de 4'-fosfato y oligonucleotidos que los comprenden.
|
US11541078B2
(en)
|
2016-09-20 |
2023-01-03 |
Cedars-Sinai Medical Center |
Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
|
EP3528827A4
(de)
|
2016-10-21 |
2020-11-04 |
Merck Sharp & Dohme Corp. |
Influenza-hämagglutinin-protein-impfstoffe
|
KR102487144B1
(ko)
|
2016-11-21 |
2023-01-12 |
에이리온 테라퓨틱스, 인코포레이티드 |
큰 물질의 경피 전달
|
CA3047140A1
(en)
|
2017-01-09 |
2018-07-12 |
Oisin Biotechnologies |
Constructs for expression of therapeutic proteins in target cells
|
MX2019010155A
(es)
|
2017-02-27 |
2020-12-10 |
Translate Bio Inc |
Arnm de cftr optimizado por codón novedoso.
|
AU2018255346B2
(en)
|
2017-04-19 |
2024-05-02 |
Capricor, Inc. |
Methods and compositions for treating skeletal muscular dystrophy
|
AU2018268859A1
(en)
|
2017-05-16 |
2019-12-12 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
乳酸脱水素酵素A(LDHA)iRNA組成物及びその使用方法
|
CA3070453A1
(en)
|
2017-07-21 |
2019-01-24 |
Buck Institute For Research On Aging |
S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
|
US11633365B2
(en)
|
2017-08-04 |
2023-04-25 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
JP6388700B2
(ja)
*
|
2017-10-20 |
2018-09-12 |
富士フイルム株式会社 |
脂質粒子の製造法および脂質粒子を有する核酸送達キャリア
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
WO2019101882A1
(en)
|
2017-11-23 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating dengue virus infection
|
US20200308588A1
(en)
|
2017-12-18 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
US11660355B2
(en)
|
2017-12-20 |
2023-05-30 |
Cedars-Sinai Medical Center |
Engineered extracellular vesicles for enhanced tissue delivery
|
CA3088546A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Sharp & Dohme Corp. |
Stabilized rsv f proteins and uses thereof
|
WO2019204666A1
(en)
*
|
2018-04-18 |
2019-10-24 |
Oisin Biotechnologies, Inc. |
Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
GB2589795B
(en)
*
|
2018-06-19 |
2022-09-07 |
Univ Texas |
Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
|
US11174500B2
(en)
|
2018-08-24 |
2021-11-16 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
WO2020051223A1
(en)
|
2018-09-04 |
2020-03-12 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for organ specific delivery of nucleic acids
|
CN112424355A
(zh)
|
2018-09-18 |
2021-02-26 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
EP3856146A4
(de)
|
2018-09-28 |
2022-07-06 |
Nutcracker Therapeutics, Inc. |
Lipidnanopartikelformulierungen mit lipidierten kationischen peptidverbindungen für die nukleinsäureabgabe
|
CN113166783A
(zh)
|
2018-10-09 |
2021-07-23 |
不列颠哥伦比亚大学 |
包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
EP3947681A1
(de)
|
2019-03-29 |
2022-02-09 |
Dicerna Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von kras-assoziierten erkrankungen oder störungen
|
US20220177880A1
(en)
|
2019-05-03 |
2022-06-09 |
Dicerna Pharmaceuticals, Inc. |
Double-stranded nucleic acid inhibitor molecules with shortened sense strands
|
EP3999642A1
(de)
|
2019-07-19 |
2022-05-25 |
Flagship Pioneering Innovations VI, LLC |
Rekombinasezusammensetzungen und verfahren zur verwendung
|
EP4007812A1
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen der serpinfamilie f element 2 (serpinf2) und verfahren zu deren verwendung
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
MX2022001896A
(es)
|
2019-08-16 |
2022-06-02 |
Regeneron Pharma |
Formulaciones anti-c5 de alta concentracion.
|
US20220280427A1
(en)
|
2019-09-06 |
2022-09-08 |
Generation Bio Co. |
Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof
|
WO2021076828A1
(en)
|
2019-10-18 |
2021-04-22 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
EP4048793A1
(de)
|
2019-10-22 |
2022-08-31 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c3 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
MX2022004712A
(es)
|
2019-10-25 |
2022-08-04 |
Regeneron Pharma |
Regimenes de dosificacion para tratar o prevenir enfermedades asociadas a c5.
|
EP4051795A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt)-irna-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
BR112022009216A2
(pt)
|
2019-11-13 |
2022-08-02 |
Alnylam Pharmaceuticals Inc |
Métodos e composições para tratar um distúrbio associado a angiotensinogênio (agt)
|
BR112022007481A2
(pt)
|
2019-11-22 |
2022-07-12 |
Generation Bio Co |
Lipídios ionizáveis e composições de nanopartículas dos mesmos
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
IL293824A
(en)
|
2019-12-13 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Compositions of RNA material (c9orf72) human chromosome 9 open reading frame 72 and methods of using them
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US20230123981A1
(en)
|
2020-01-15 |
2023-04-20 |
Dicerna Pharmaceuticals, Inc. |
4'-o-methylene phosphonate nucleic acids and analogues thereof
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
CA3171654A1
(en)
|
2020-02-18 |
2021-08-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
KR20220150380A
(ko)
|
2020-03-06 |
2022-11-10 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제 (KHK) iRNA 조성물 및 이의 사용 방법
|
JP2023520764A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用
|
JP2023520763A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
ゴーシェ治療薬を発現するための非ウイルス性dnaベクター及びその使用
|
EP4127168A1
(de)
|
2020-03-26 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus-irna-zusammensetzungen und verfahren zur verwendung davon
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
WO2021207189A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
WO2021213924A1
(en)
|
2020-04-22 |
2021-10-28 |
BioNTech SE |
Coronavirus vaccine
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
KR20230017789A
(ko)
|
2020-04-30 |
2023-02-06 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
|
EP4150086A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von leucinreicher repeat-kinase 2 (lrrk2)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
EP4150078A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten editierung von argininosuccinat-lyase (asl)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
CA3162416C
(en)
|
2020-05-15 |
2023-07-04 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
JP2023526423A
(ja)
|
2020-05-20 |
2023-06-21 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
免疫原性組成物及びその使用
|
EP4153224A1
(de)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Coronavirus-antigen-zusammensetzungen und ihre verwendungen
|
CA3180101A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
WO2021243301A2
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
BR112022024420A2
(pt)
|
2020-06-18 |
2023-01-17 |
Alnylam Pharmaceuticals Inc |
Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
|
US20230277675A1
(en)
|
2020-08-04 |
2023-09-07 |
Dicerna Pharmaceuticals, Inc. |
Systemic delivery of oligonucleotides
|
CA3193746A1
(en)
|
2020-09-03 |
2022-03-10 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
EP4244355A1
(de)
|
2020-11-13 |
2023-09-20 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor-v (f5)-irna-zusammensetzungen und verfahren zur verwendung davon
|
KR20230124927A
(ko)
|
2020-11-25 |
2023-08-28 |
아카제라 메디신즈, 인크. |
핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CA3206285A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering, Inc. |
Compositions of modified trems and uses thereof
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022174000A2
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
WO2022182872A2
(en)
|
2021-02-24 |
2022-09-01 |
Alladapt Immunotherapeutics, Inc. |
Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
|
WO2022182864A1
(en)
|
2021-02-25 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods and methods of use thereof
|
JP2024515423A
(ja)
|
2021-02-26 |
2024-04-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
AU2022231003A1
(en)
|
2021-03-04 |
2023-09-14 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
CA3214499A1
(en)
|
2021-03-29 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (htt) irna agent compositions and methods of use thereof
|
EP4313109A1
(de)
|
2021-03-31 |
2024-02-07 |
Flagship Pioneering Innovations V, Inc. |
Apotransmission-polypeptide und deren verwendung bei der behandlung von krebs
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
AU2022264478A1
(en)
|
2021-04-26 |
2023-10-12 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
IL308404A
(en)
|
2021-04-27 |
2024-01-01 |
Generation Bio Co |
Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
|
EP4329884A1
(de)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Nichtvirale dna-vektoren zur expression von anti-coronavirus-antikörpern und verwendungen davon
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4341401A1
(de)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Natriumglucose-cotransporter-2-(sglt2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022246023A1
(en)
|
2021-05-20 |
2022-11-24 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(de)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024521907A
(ja)
|
2021-06-04 |
2024-06-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ヒト9番染色体オープンリーディングフレーム72(C9ORF72)iRNA剤組成物及びその使用方法
|
AR126070A1
(es)
|
2021-06-08 |
2023-09-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
|
CN117642380A
(zh)
|
2021-06-14 |
2024-03-01 |
世代生物公司 |
阳离子脂质及其组合物
|
EP4355098A1
(de)
*
|
2021-06-17 |
2024-04-24 |
The Regents of the University of California |
Vesikelformulierungen zur verabreichung von antifungalen nukleinsäuren
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
EP4363574A1
(de)
|
2021-06-29 |
2024-05-08 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
AU2022303164A1
(en)
|
2021-06-30 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
AU2022314619A1
(en)
|
2021-07-21 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
EP4377457A1
(de)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem-zusammensetzungen und verwendungen davon
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
EP4381067A1
(de)
|
2021-08-03 |
2024-06-12 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
CN113636931B
(zh)
*
|
2021-08-05 |
2024-02-13 |
康龙化成(宁波)科技发展有限公司 |
基因编码化合物库起始头片段化合物及其在基因编码化合物库合成上的应用
|
BR112024001923A2
(pt)
|
2021-08-13 |
2024-04-30 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator xii (f12) e métodos de usos das mesmas
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232635A1
(en)
|
2021-09-17 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
IL312399A
(en)
|
2021-10-29 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
Complement factor B (CFB) iRNA compositions and methods of using them
|
CA3238370A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
CA3238735A1
(en)
|
2021-11-24 |
2023-06-01 |
Jennifer A. Nelson |
Immunogenic compositions and their uses
|
CA3240691A1
(en)
|
2021-12-17 |
2023-06-22 |
Alexandra Sophie DE BOER |
Methods for enrichment of circular rna under denaturing conditions
|
WO2023122745A1
(en)
|
2021-12-22 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2023122789A1
(en)
|
2021-12-23 |
2023-06-29 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
TW202409283A
(zh)
|
2022-05-13 |
2024-03-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
雙股dna組合物及相關方法
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
WO2024097664A1
(en)
|
2022-10-31 |
2024-05-10 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for purifying polyribonucleotides
|
WO2024102799A1
(en)
|
2022-11-08 |
2024-05-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
WO2024119039A2
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticles and uses thereof
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
WO2024119103A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|